JPWO2019229525A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019229525A5 JPWO2019229525A5 JP2020559390A JP2020559390A JPWO2019229525A5 JP WO2019229525 A5 JPWO2019229525 A5 JP WO2019229525A5 JP 2020559390 A JP2020559390 A JP 2020559390A JP 2020559390 A JP2020559390 A JP 2020559390A JP WO2019229525 A5 JPWO2019229525 A5 JP WO2019229525A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- subject
- administration
- control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 230
- 208000003251 Pruritus Diseases 0.000 claims description 70
- 102000004965 antibodies Human genes 0.000 claims description 59
- 108090001123 antibodies Proteins 0.000 claims description 59
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 50
- 201000008937 atopic dermatitis Diseases 0.000 claims description 50
- 201000010099 disease Diseases 0.000 claims description 29
- 238000011156 evaluation Methods 0.000 claims description 24
- 206010022437 Insomnia Diseases 0.000 claims description 22
- 206010060875 Uraemic pruritus Diseases 0.000 claims description 20
- 238000007920 subcutaneous administration Methods 0.000 claims description 20
- 206010072757 Chronic spontaneous urticaria Diseases 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 238000001631 haemodialysis Methods 0.000 claims description 14
- 230000000322 hemodialysis Effects 0.000 claims description 14
- 230000001225 therapeutic Effects 0.000 claims description 14
- 102100008428 CCL2 Human genes 0.000 claims description 12
- 101700006000 CCL2 Proteins 0.000 claims description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 200000000018 inflammatory disease Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 201000011486 lichen planus Diseases 0.000 claims description 10
- 201000009053 neurodermatitis Diseases 0.000 claims description 9
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 claims description 8
- 239000000902 placebo Substances 0.000 claims description 8
- 229940068196 placebo Drugs 0.000 claims description 8
- 206010002855 Anxiety Diseases 0.000 claims description 6
- 206010057666 Anxiety disease Diseases 0.000 claims description 6
- 208000010217 Blepharitis Diseases 0.000 claims description 6
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims description 6
- 206010011659 Cutaneous amyloidosis Diseases 0.000 claims description 6
- 206010030124 Oedema peripheral Diseases 0.000 claims description 6
- 101710043203 P23p89 Proteins 0.000 claims description 6
- 206010034277 Pemphigoid Diseases 0.000 claims description 6
- 206010038444 Renal failure chronic Diseases 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 230000001684 chronic Effects 0.000 claims description 6
- 201000000522 chronic kidney disease Diseases 0.000 claims description 6
- 230000000007 visual effect Effects 0.000 claims description 6
- 230000003442 weekly Effects 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 206010013774 Dry eye Diseases 0.000 claims description 4
- 208000009889 Herpes Simplex Diseases 0.000 claims description 4
- 206010023332 Keratitis Diseases 0.000 claims description 4
- 102100019816 OSMR Human genes 0.000 claims description 4
- 101700032890 OSMR Proteins 0.000 claims description 4
- 206010067152 Oral herpes Diseases 0.000 claims description 4
- 208000006641 Skin Disease Diseases 0.000 claims description 4
- 231100000494 adverse effect Toxicity 0.000 claims description 4
- 229910021320 cobalt-lanthanum-strontium oxide Inorganic materials 0.000 claims description 4
- 201000004624 dermatitis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001329 hyperkeratotic Effects 0.000 claims description 4
- 230000002757 inflammatory Effects 0.000 claims description 4
- 201000009240 nasopharyngitis Diseases 0.000 claims description 4
- 230000001575 pathological Effects 0.000 claims description 4
- 230000001823 pruritic Effects 0.000 claims description 4
- 231100000197 serious side effect Toxicity 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 229940109239 Creatinine Drugs 0.000 claims description 3
- 206010037083 Prurigo Diseases 0.000 claims description 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 3
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 208000009863 Chronic Kidney Failure Diseases 0.000 claims description 2
- 208000005679 Eczema Diseases 0.000 claims description 2
- 208000001083 Kidney Disease Diseases 0.000 claims description 2
- 206010054107 Nodule Diseases 0.000 claims description 2
- 206010046736 Urticarias Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 230000003111 delayed Effects 0.000 claims description 2
- 231100000406 dermatitis Toxicity 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 231100001003 eczema Toxicity 0.000 claims description 2
- 201000000523 end stage renal failure Diseases 0.000 claims description 2
- 230000005713 exacerbation Effects 0.000 claims description 2
- 230000001404 mediated Effects 0.000 claims description 2
- 201000004681 psoriasis Diseases 0.000 claims description 2
- 238000007390 skin biopsy Methods 0.000 claims description 2
- 230000000699 topical Effects 0.000 claims description 2
- 208000008585 Mastocytosis Diseases 0.000 claims 3
- 102000004420 EC 2.7.3.2 Human genes 0.000 claims 1
- 108010042126 EC 2.7.3.2 Proteins 0.000 claims 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024066665A JP2024096933A (ja) | 2018-04-25 | 2024-04-17 | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662607P | 2018-04-25 | 2018-04-25 | |
| US62/662,607 | 2018-04-25 | ||
| US201862718324P | 2018-08-13 | 2018-08-13 | |
| US62/718,324 | 2018-08-13 | ||
| US201862765033P | 2018-08-16 | 2018-08-16 | |
| US62/765,033 | 2018-08-16 | ||
| US201862731618P | 2018-09-14 | 2018-09-14 | |
| US62/731,618 | 2018-09-14 | ||
| US201862757047P | 2018-11-07 | 2018-11-07 | |
| US62/757,047 | 2018-11-07 | ||
| US201862775350P | 2018-12-04 | 2018-12-04 | |
| US62/775,350 | 2018-12-04 | ||
| US201962789434P | 2019-01-07 | 2019-01-07 | |
| US62/789,434 | 2019-01-07 | ||
| US201962794356P | 2019-01-18 | 2019-01-18 | |
| US62/794,356 | 2019-01-18 | ||
| PCT/IB2019/000619 WO2019229525A2 (fr) | 2018-04-25 | 2019-04-25 | TRAITEMENT DE MALADIES OU DE TROUBLES DE LA PEAU PAR LA FOURNITURE D'UN ANTICORPS ANTI-OSMRβ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024066665A Division JP2024096933A (ja) | 2018-04-25 | 2024-04-17 | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522241A JP2021522241A (ja) | 2021-08-30 |
| JPWO2019229525A5 true JPWO2019229525A5 (fr) | 2022-05-06 |
Family
ID=68234020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559390A Withdrawn JP2021522241A (ja) | 2018-04-25 | 2019-04-25 | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 |
| JP2024066665A Pending JP2024096933A (ja) | 2018-04-25 | 2024-04-17 | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024066665A Pending JP2024096933A (ja) | 2018-04-25 | 2024-04-17 | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210054085A1 (fr) |
| EP (1) | EP3784347A2 (fr) |
| JP (2) | JP2021522241A (fr) |
| KR (1) | KR20210018808A (fr) |
| CN (1) | CN112533675A (fr) |
| AU (1) | AU2019276779A1 (fr) |
| BR (1) | BR112020021739A2 (fr) |
| CA (1) | CA3096582A1 (fr) |
| MX (1) | MX2020011172A (fr) |
| SG (1) | SG11202010034WA (fr) |
| WO (1) | WO2019229525A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4209227A4 (fr) * | 2020-09-01 | 2024-05-29 | Chugai Seiyaku Kabushiki Kaisha | Composition pharmaceutique pour la prévention et/ou le traitement du prurit en dialyse contenant comme principe actif un antagoniste de l'il-31 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012202218B2 (en) * | 2005-02-14 | 2014-05-22 | National Jewish Medical And Research Center | Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells |
| CA2595877A1 (fr) * | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methodes de traitement des maladies mediees par des cellules positives a l'egard de l'antigene lymphocytaire cutane |
| JP6214010B2 (ja) * | 2012-05-11 | 2017-10-18 | 公立大学法人和歌山県立医科大学 | 抗オンコスタチンｍ受容体ベータ抗体 |
| NZ713636A (en) * | 2013-05-30 | 2022-07-01 | Kiniksa Pharmaceuticals Ltd | Oncostatin m receptor antigen binding proteins |
| TWI697334B (zh) * | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| MX2017009695A (es) * | 2015-01-29 | 2018-04-10 | Univ Oxford Innovation Ltd | Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd). |
| KR102514173B1 (ko) * | 2015-04-14 | 2023-03-27 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
-
2019
- 2019-04-25 US US17/050,261 patent/US20210054085A1/en not_active Abandoned
- 2019-04-25 KR KR1020207033800A patent/KR20210018808A/ko unknown
- 2019-04-25 SG SG11202010034WA patent/SG11202010034WA/en unknown
- 2019-04-25 AU AU2019276779A patent/AU2019276779A1/en active Pending
- 2019-04-25 MX MX2020011172A patent/MX2020011172A/es unknown
- 2019-04-25 CN CN201980039355.2A patent/CN112533675A/zh active Pending
- 2019-04-25 JP JP2020559390A patent/JP2021522241A/ja not_active Withdrawn
- 2019-04-25 WO PCT/IB2019/000619 patent/WO2019229525A2/fr unknown
- 2019-04-25 EP EP19786854.0A patent/EP3784347A2/fr active Pending
- 2019-04-25 CA CA3096582A patent/CA3096582A1/fr active Pending
- 2019-04-25 BR BR112020021739-5A patent/BR112020021739A2/pt unknown
-
2023
- 2023-03-30 US US18/193,393 patent/US20240101690A1/en active Pending
-
2024
- 2024-04-17 JP JP2024066665A patent/JP2024096933A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nishimoto et al. | Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study | |
| Sabatelli et al. | Pure motor chronic inflammatory demyelinating polyneuropathy | |
| JP6190368B2 (ja) | 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法 | |
| JP6424210B2 (ja) | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| US20080032989A1 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
| JPH0776179B2 (ja) | 免疫学的因子を含む病気の治療用組成物 | |
| JP2022121658A (ja) | アミロイドーシスを処置するための組成物 | |
| KR20120129904A (ko) | 안내 혈관 신생 및/또는 안내 혈관 투과성 항진을 수반하는 질환의 예방 또는 치료를 위한 의약 | |
| Benucci et al. | Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis | |
| JP2024001125A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2019512472A5 (fr) | ||
| Nishimoto et al. | Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study | |
| WO2012105610A1 (fr) | Agent médicinal pour la prévention ou le traitement de maladies associées à une néovascularisation intraoculaire et/ou une hyperperméabilité vasculaire intraoculaire | |
| JP2024096933A (ja) | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 | |
| KR20180017145A (ko) | 소양증의 치료 | |
| JPWO2019229525A5 (fr) | ||
| JPWO2019222055A5 (fr) | ||
| Karanikolas et al. | Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. | |
| KR20240027045A (ko) | 폐쇄성 수면 무호흡의 치료 방법 | |
| Handa et al. | Cataract surgery in Behcet’s disease patients one week after infliximab administration | |
| Jaimes-Hernández et al. | Rheumatoid arthritis treatment with weekly leflunomide: an open-label study. | |
| US10071077B2 (en) | Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation | |
| RU2437666C1 (ru) | Способ лечения ревматоидного артрита | |
| EP2726078B1 (fr) | Méthodes de traitement de maladies immunitaires du système nerveux par l'administration d'un composé comprenant des agents qui inhibent l'activité des récepteurs de prokinéticine |